Fosun Pharmaceutical

BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China

Wednesday, August 5, 2020 - 9:30am

BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.

Key Points: 
  • BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China.
  • During the clinical development stage, BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe.
  • If the vaccine receives marketing authorization in China, Fosun Pharma will exclusively commercialize the vaccine in Mainland China, Hong Kong and Macau Special Administration Regions and in Taiwan.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

Sensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China

Tuesday, July 28, 2020 - 1:30pm

Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China.

Key Points: 
  • Mr. Suen brings to Sensus nearly 20 years of business development, sales and regulatory experience supporting the distribution of U.S. medical devices and other products throughout Asia and in particular China.
  • From 2010 to 2016 he was Senior Manager, Business Development and Regulatory at Chindex International, prior to its acquisition by Fosun Pharma.
  • We worked with Benson when he was with our China distributor, and know his abilities first-hand.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa

Wednesday, April 29, 2020 - 5:50pm

Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.

Key Points: 
  • Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.
  • Mr. Wu Yifang, President and CEO of Fosun Pharma, said, "Fosun Pharma has been operating in Africa for over decade and has nearly 1,000 employees there.
  • We are striving to control the spread of the epidemic by strengthening various case management measures."
  • Fosun Pharma hopes that these materials will help alleviate the burden on local health systems, facilitating the countries to reach their malaria prevention and control targets.

Fosun Pharma Receives FDA Emergency Use Authorization (EUA) For Its COVID-19 RT-PCR Detection Kit

Sunday, April 19, 2020 - 1:00pm

SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.

Key Points: 
  • SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.
  • The testing kit which was self-developed by Fosun Long March, a wholly-owned subsidiary of Fosun Pharma, has received the medical device registration certificate issued by the China National Medical Products Administration (NMPA) and granted CE certification from the European Union ("EU").
  • Fosun Pharma has been engaged in the business of PCR hepatitis B virus diagnostic reagents since its establishment in 1994.
  • According to the company's FY2019 earnings results, the revenue of Fosun Pharma increased by 14.72% to RMB28,585million as compared to 2018.

From China to the World, Fosun's Fight against COVID-19 Continues

Tuesday, April 7, 2020 - 2:57pm

Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.

Key Points: 
  • Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.
  • Chen Qiyu, Co-CEO of Fosun International and Chairman of Fosun Pharma, expressed his gratitude to the experts from all over the world.
  • Chen said: "Since January 23, Fosun's Wuhan Jihe Hospital is listed as a COVID-19 designated treatment hospital.
  • We have invested in the fight against the epidemic in all aspects.

From China to the World, Fosun's Fight against COVID-19 Continues

Tuesday, April 7, 2020 - 2:49pm

Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.

Key Points: 
  • Since the outbreak of the coronavirus pandemic, Fosun has actively participated in the fight against the epidemic in China and around the world, and has joined hands to provide assistance to the world.
  • Chen Qiyu, Co-CEO of Fosun International and Chairman of Fosun Pharma, expressed his gratitude to the experts from all over the world.
  • Chen said: "Since January 23, Fosun's Wuhan Jihe Hospital is listed as a COVID-19 designated treatment hospital.
  • We have invested in the fight against the epidemic in all aspects.

BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat

Monday, March 16, 2020 - 6:00am

As part of its global development program, BioNTech announced today a strategic alliance with Fosun Pharma to jointly develop its COVID-19 vaccine in China.

Key Points: 
  • As part of its global development program, BioNTech announced today a strategic alliance with Fosun Pharma to jointly develop its COVID-19 vaccine in China.
  • In addition, BioNTech is in advanced discussions with its existing collaborator Pfizer regarding the development of the vaccine outside China.
  • We feel a duty to exploit our full technology and immunotherapy expertise to help address the COVID-19 pandemic emergency.
  • BNT162 is BioNTechs mRNA vaccine program aimed at preventing COVID-19 infection and is the first product candidate from Project Lightspeed.

BioNTech and Fosun Pharma form COVID-19 vaccine strategic alliance in China

Monday, March 16, 2020 - 6:00am

If approved, Fosun Pharma will commercialize the vaccine in China.

Key Points: 
  • If approved, Fosun Pharma will commercialize the vaccine in China.
  • BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe along with its partner Polymun .
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Fosun Pharma, Stock Symbol: 600196.SH, 02196.HK) is a leading healthcare group founded in China.
  • These forward-looking statements may include, but may not be limited to, the ability of BioNTech and Fosun Pharma to develop and commercialize a vaccine for COVID-19; the potential for a broader collaboration between BioNTech and Fosun Pharma; and the ability to consummate an equity investment by Fosun Pharma in BioNTech.

Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

Monday, December 2, 2019 - 9:01pm

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 8065608.

Key Points: 
  • To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 8065608.
  • Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines.
  • To efficiently bring its treatments to market, Ardelyx is pursuing strategic collaborations for tenapanor for IBS-C and hyperphosphatemia in certain territories.
  • Ardelyx has established agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.

Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

Monday, November 25, 2019 - 11:00pm

In return, Kyowa Kirin will pay Ardelyx $10 million ($5 million a year for two years) to support the ongoing research.

Key Points: 
  • In return, Kyowa Kirin will pay Ardelyx $10 million ($5 million a year for two years) to support the ongoing research.
  • Under the second agreement, Kyowa Kirin has made a $20 million equity investment in Ardelyx at $6.96 for 2,873,563 shares.
  • Ardelyx and Kyowa Kirin initially established a collaboration partnership in November 2017 througha license agreement that provided Kyowa Kirin with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.
  • Ardelyx has established agreements with Kyowa Kirin (formerly known as Kyowa Hakko Kirin) in Japan, Fosun Pharma in China and Knight Therapeutics in Canada.